The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome
暂无分享,去创建一个
I. Ellis | A. Green | D. Powe | E. Rakha | E. Paish | R. Macmillan | E. Stylianou | S. El-Sheikh | C. Burney | Christopher J. Granger
[1] Ian O Ellis,et al. Prognostic markers in triple‐negative breast cancer , 2007, Cancer.
[2] Douglas Macmillan,et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. , 2006, European journal of cancer.
[3] V. Jordan,et al. Steroid receptors and their role in the biology and control of breast cancer growth. , 2006, Seminars in oncology.
[4] K. Wernecke,et al. Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer , 2006, Virchows Archiv.
[5] G. Ball,et al. High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.
[6] E. McDermott,et al. Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer , 2005, Clinical Cancer Research.
[7] I. Ellis,et al. The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.
[8] E. McDermott,et al. Inverse relationship between ER-β and SRC-1 predicts outcome in endocrine-resistant breast cancer , 2004, British Journal of Cancer.
[9] I. Ellis,et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma , 2004, British Journal of Cancer.
[10] E. McDermott,et al. Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1 , 2004, Journal of Clinical Pathology.
[11] E. Kubista,et al. Expression of Sex Steroid Receptors and their Co-Factors in Normal and Malignant Breast Tissue: AIB1 is a Carcinoma-Specific Co-Activator , 2003, Breast Cancer Research and Treatment.
[12] Baljit Singh,et al. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue , 2001, Breast Cancer Research and Treatment.
[13] Arnold D K Hill,et al. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. , 2004, The Journal of clinical endocrinology and metabolism.
[14] S. Jiang,et al. Estrogen receptor corepressors -- a role in human breast cancer? , 2003, Endocrine-related cancer.
[15] S. Pinder,et al. Loss of CD59 expression in breast tumours correlates with poor survival , 2003, The Journal of pathology.
[16] J. Stec,et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] H. Iwata,et al. Clinical significance of the expression of estrogen receptors α and β for endocrine therapy of breast cancer , 2003, Cancer Chemotherapy and Pharmacology.
[18] R. Schiff,et al. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. , 2003, Cancer research.
[19] I. Bièche,et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] H. Iwata,et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. , 2003, Cancer chemotherapy and pharmacology.
[21] Z. Nawaz,et al. The roles of sex steroid receptor coregulators in cancer , 2002, Molecular Cancer.
[22] M. Erdos,et al. p300 Modulates the BRCA1 inhibition of estrogen receptor activity. , 2002, Cancer research.
[23] I. Ellis,et al. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.
[24] C. Cordon-Cardo,et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. , 2001, The American journal of pathology.
[25] M. Southey,et al. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. , 2001, Cancer research.
[26] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[27] J. Font de Mora,et al. AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor , 2000, Molecular and Cellular Biology.
[28] H. Ruffner,et al. CBP/p300 interact with and function as transcriptional coactivators of BRCA1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Kurebayashi,et al. Expression Levels of Estrogen Receptor-α, Estrogen Receptor-β, Coactivators, and Corepressors in Breast Cancer , 2000 .
[30] K. Tanaka,et al. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] I. Ellis,et al. Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.
[32] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[33] C. Glass,et al. Co-activators and co-repressors in the integration of transcriptional responses. , 1998, Current opinion in cell biology.
[34] Christopher K. Glass,et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function , 1997, Nature.
[35] Dieter Niederacher,et al. Multistep carcinogenesis of breast cancer and tumour heterogeneity , 1997, Journal of Molecular Medicine.
[36] B. O’Malley,et al. CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[37] C. Osborne,et al. Aberrant Subcellular Localization of BRCA1 in Breast Cancer , 1995, Science.
[38] R. Blamey,et al. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long‐term follow‐up , 1992, Histopathology.
[39] E B Cox,et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.